Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848428 | 0.81 | NOS3 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL12848424 | 0.81 | NOS3 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL6124109 | 0.76 | PDCD1 (0.38) | — | |
| SCHEMBL12197666 | 0.75 | CYP1A2 (0.33) | — | |
| SCHEMBL28059983 | 0.72 | ADORA2A (0.35) | — | |
| SCHEMBL5950443 | 0.72 | NOS3 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL25910823 | 0.70 | NOS3 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL6129987 | 0.70 | NOS3 (0.35) | NOS3NOS1NOS2 | |
| SCHEMBL30585581 | 0.70 | NOS3 (0.35) | NOS3NOS1NOS2 | |
| SCHEMBL4788899 | 0.69 | ADORA1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-20230148184-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200247814-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-08-06 | — | — | US | disclosed |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-12 | — | — | US | disclosed |
| US-20180169250-A1 | COVALENT LINKERS IN ANTIBODY-DRUG CONJUGATES AND METHODS OF MAKING AND USING THE SAME | REMEGEN CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| US-20180055948-A1 | Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same | REMEGEN CO., LTD. (CN) | 2018-03-01 | — | — | US | disclosed |
| US-9884127-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| WO-2017007756-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | RODIN THERAPEUTICS, INC (US) | 2017-01-12 | — | — | WO | disclosed |
| US-20150105540-A1 | DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS | SORRENTO THERAPEUTICS INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | NOS3 4121/4885NOS1 3843/4885NOS2 3301/4885 |
| US-20180169250-A1 | COVALENT LINKERS IN ANTIBODY-DRUG CONJUGATES AND METHODS OF MAKING AND USING THE SAME | DHFR, FCGR1A, ADCY4 | NOS3 2932/4885NOS1 2794/4885NOS2 2362/4885 |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | NOS3 4121/4885NOS1 3843/4885NOS2 3301/4885 |
| US-20200247814-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | NOS3 4121/4885NOS1 3843/4885NOS2 3301/4885 |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | NOS3 4121/4885NOS1 3843/4885NOS2 3301/4885 |
| US-20230148184-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | NOS3 1216/4885NOS1 1941/4885NOS2 1934/4885 |
| US-20180055948-A1 | Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same | DHFR, FCGR1A, ADCY4 | NOS3 2932/4885NOS1 2794/4885NOS2 2362/4885 |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | NOS3 248/4885NOS1 335/4885NOS2 211/4885 |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | PAICS, CES2, DNPEP | NOS3 4229/4885NOS1 4278/4885NOS2 3945/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | NOS3 2156/4885NOS1 2576/4885NOS2 3027/4885 |
| US-20150105540-A1 | DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS | ERBB2, ABCG2, DYNLL2 | NOS3 4785/4885NOS1 4803/4885NOS2 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.